title: Role of metalloproteases in the release of the IL-1 type II decoy receptor.
abstract: The IL-1 type II receptor (decoy RII) is a nonsignaling molecule the only established function of which is to capture IL-1 and prevent it from interacting with signaling receptor. The decoy RII is released in a regulated way from the cell surface. Here, we reported that hydroxamic acid inhibitors of matrix metalloproteases inhibit different pathways of decoy RII release, including the following: (a) the slow (18 h) gene expression-dependent release from monocytes and polymorphonuclear cells exposed to dexamethasone; (b) rapid release (minutes) from myelomonocytic cells exposed to tumor necrosis factor, chemoattractants, or phorbol myristate acetate; (c) phorbol myristate acetate-induced release from decoy RII-transfected fibroblasts and B cells. Inhibition of release was associated with increased surface expression of decoy RII. Inhibitors of other protease classes did not substantially affect release. However, serine protease inhibitors increased the molecular mass of the decoy RII released from polymorphonuclear cells from 45 to 60 kDa. Thus, irrespective of the pathway responsible for release and of the cellular context, matrix metalloproteases, rather than differential splicing, play a key role in production of soluble decoy RII.
authors.affiliation: Department of Immunology and Cell Biology, Istituto di Ricerche Farmacologiche "Mario Negri," Via Eritrea 62, 20157 Milano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Orlando
authors.forename: M
authors.initials: M
authors.lastname: Sironi
authors.forename: G
authors.initials: G
authors.lastname: Bianchi
authors.forename: A H
authors.initials: AH
authors.lastname: Drummond
authors.forename: D
authors.initials: D
authors.lastname: Boraschi
authors.forename: D
authors.initials: D
authors.lastname: Yabes
authors.forename: A
authors.initials: A
authors.lastname: Mantovani
mesh_terms: D017398:Alternative Splicing; D003907:Dexamethasone / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D016393:Lymphoma, B-Cell / Q000378:metabolism; D008666:Metalloendopeptidases / Q000378:metabolism*; D008970:Molecular Weight; D009000:Monocytes / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D017472:Receptors, Interleukin-1 / Q000378:metabolism*; D053574:Receptors, Interleukin-1 Type II; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D011480:Protease Inhibitors; D017472:Receptors, Interleukin-1; D053574:Receptors, Interleukin-1 Type II; D013876:Thiophenes; D010649:Phenylalanine; D003907:Dexamethasone; C080985:batimastat; D008666:Metalloendopeptidases; D013755:Tetradecanoylphorbol Acetate